Cytokinetics lung cancer trial fails
San Francisco Business Times - 2:51 PM PST Thursday
Cytokinetics Inc. said Thursday that a clinical trial of ispinesib, an experimental lung cancer treatment, failed.
The South San Francisco drug company (NASDAQ: CYTK) said the Phase II trial, run by GlaxoSmithKline, failed to meet the criteria to advance to the next stage of clinical testing.


Tina Radcliffe spent ten years as a Oncology Certified R.N. working with in-patients on oncology and med-surg units. She also has a background in home health and geriatrics. Her other experiences include ... .. 
































